Genomas, Inc.

Publications

Date	Publication
11/2011	Mechanisms of Statin-Induced Myalgia Assessed by Physiogenomic Associations. Atherosclerosis
9/2011	Guidance of Pharmacotherapy in a Complex Psychiatric Case by CYP450 DNA Typing. Journal of the American Academy of Nurse Practitioners
8/2011	Physiogenomic Analysis of CYP450 Drug Metabolism Correlates Dyslipidemia with Pharmacogenetic Functional Status in Psychiatric Patients. Biomarkers in Medicine
8/2011	Novel Drug Metabolism Indices for Pharmacogenetic Functional Status Based on Combinatory Genotyping of CYP2C9, CYP2C19 and CYP2D6 Genes. Biomarkers in Medicine
8/2011	Validation of Candidate Genes Associated with Cardiovascular Risk Factors in Psychiatric Patients. Progress in Neuro-Psychopharmacology & Biological Psychiatry
7/2010	Physiogenomic Analysis of Statin-Treated Patients: Domain Specific Counter Effects within the ACACB Gene on LDL Cholesterol? Pharmacogenomics
7/2010	Clinical Practice Considerations. In: Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice. Valdes R, Payne D, Linder MW, editors. The National Academy of Clinical Biochemistry: Laboratory Medicine Practice Guidelines. 23–28
7/2010	Pharmacology and Population Genetics Considerations and Their Applications in Pharmacogenetics. In: Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice. Valdes R, Payne D, Linder MW, editors. The National Academy of Clinical Biochemistry: Laboratory Medicine Practice Guidelines. 3–10
5/2010	Implementing genotype-guided antithrombotic therapy. Future Cardiology, 6 (3): 409-424
12/2009	Acetyl-coenzyme A carboxylase alpha gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels. Schizophrenia Research, 115: 136-140
10/2009	Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: Implications for Warfarin Management in Hispanics. Ethnicity & Disease, 19: 390-395
9/2009	Bringing DNA-Guided Medicine to the Hispanic Population. Puerto Rico Health Sciences Journal, 28 (3): 266-267, cover
4/2009	Physiogenomic Analysis of the Puerto Rican Population. Pharmacogenomics, 10 (4): 565-577
2/2009	Physiogenomic comparison of Edema and BMI in Patients Receiving Rosiglitazone or Pioglitazone. Clinica Chimica Acta, 400: 48-55
1/2009	Combining fMRI and SNP Data to Investigate Connections Between Brain Function and Genetics Using Parallel ICA. Human Brain Mapping, 30: 241-255
12/2008	Products for Pharmacogenetic Testing in Psychiatry: A Review of Features and Clinical Realities. Clinics in Laboratory Medicine, 28: 599-617
11/2008	Increased Carrier Prevalence of Deficient CYP2C9, CYP2C19 and CYP2D6 Alleles in Depressed Patients Referred to a Tertiary Psychiatric Hospital. Personalized Medicine, 5 (6): 579-587
8/2008	Integrating Genomic Based Information into Clinical Warfarin (Coumadin®) Management: An Illustrative Case Report. Connecticut Medicine, 72 (7): 399-403
7/2008	DNA Collage and Personalized Medicine. Connecticut Medicine, 72 (6): 322-cover
6/2008	Physiogenomic Analysis of Localized fMRI Brain Activity in Schizophrenia. Annals of Biomedical Engineering, 36 (6): 877-88
5/2008	High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing. Personalized Medicine, 5 (3): 225-232
2/2008	Physiogenomic comparison of human fat loss in response to diets restrictive of carbohydrate or fat. Nutrition and Metabolism, 5: (1):4
1/2008	Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophrenia Research, 98: 40-46
11/2007	DNA-guided Decision Support. Hospital Health Networks, 81 (11): 10
9/2007	Physiogenomic Association of Statin-Related Myalgia to Serotonin Receptors. Muscle & Nerve, 36: 329-335
5/2007	Physiogenomic Comparison of Weight Profiles of Olanzapine- and Risperidone-Treated Patients. Molecular Psychiatry, 12: 474- 482
5/2007	A clinical study of the association of antipsychotics with hyperlipidemia. Schizophrenia Research, 92: 95-102
4/2007	Somatic Complications of Psychotropic Medications in a Patient with Multiple CYP2 Drug Metabolism Deficiencies. Connecticut Medicine, 71: 197-200
10/2006	Drug-induced metabolic syndrome (DIMS) in psychiatry: a diagnostic need uniquely suited to pharmacogenomics. American Association for Clinical Chemistry Press, 277-282
5/2006	High carrier prevalence of deficient and null alleles of CYP2 genes in a major USA hospital: Implications for personalized drug safety. Personalized Medicine, 3 (2): 131-137
5/2006	Physiogenomic analysis of weight loss induced by dietary carbohydrate restriction. Nutrition and Metabolism, 3: 20-30
4/2006	The Pharmacogenomics of Warfarin (Coumadin) Administration. Connecticut Medicine, 70 (4): 251-252
3/2006	Physiogenomics: Integrating systems engineering and nanotechnology for personalized health. In: The Biomedical Engineering Handbook, 3rd Edition, Bronzino JD, editor. CRC Press Taylor and Francis, 28: 1-9
3/2006	A common promoter polymorphism of the Apolipoprotein A1 gene affects exercise-induced changes in cholesterol distribution among HDL subfractions. Atherosclerosis, 185: 65-69
3/2006	Designing Physiogenomic Studies. Pharmacogenomics, 7(2): 157-158
12/2005	Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics, 6 (8): 865-872
8/2005	Personalizing public health. Personalized Medicine, 2 (3): 239-249
3/2004	Quo Vadis personalized medicine? Personalized Medicine, 1 (1): 1-7
2/2004	Genomas: Company Profile. Personalized Medicine, 1 (1): 135-139
1/2004	Pharmacogenomic data submission to the FDA: clinical pharmacology case studies. Pharmacogenomics, 5 (5): 513-517